Anapharm Bioanalytics acquires a new high sensitivity equipment: SCIEX Triple Quad 6500+ system
Anapharm Bioanalytics’ small molecule division continues to expand its capabilities with the acquisition of a new LC-MS/MS equipment tailored for method development and validation of high sensitivity assays. The new instrument increases our capabilities for peptide chemistry as well as for orally inhaled drugs such as for example Glycopyrronium; Indacaterol, Fluticasone, Salmeterol, Budesonide, Tiotropium, etc. in biological fluids.
The Triple Quad 6500+ system features multi-component IonDrive Technology including the IonDrive High Energy Detector+ that delivers revolutionary sensitivity, speed, and performance for the most challenging methods.
Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2024.READ MORE
New UPLC-MS/MS bioanalytical method for quantification of Glycopyrronium and Indacaterol
We are glad to announce that a new method has been successfully developed and validated for determination of Glycopyrronium and Indacaterol in human plasma by LC/MS/MS with a calibration range of 1-200 pg/mL and 2-250 pg/mL, respectively.READ MORE
Challenges in the Detection of Metabolic Biomarkers Using a Multi Plex Assay
A 5 Plex method for the detection of metabolic biomarkers in human plasma was developed using the U-PLEX technology on the MSD platform.
The complexities surrounding this method were the establishment of endogenous QCs for each chosen biomarker and evaluating the potential use and need for buffer QCs vs matrix QCs where applicable. Additional challenges were faced while trying to ascertain a single minimum required dilution to enable accurate quantification of all biomarkers simultaneously, encompassing the different detection ranges and limits for each biomarker.READ MORE